バイオ医薬品からのウイルス感染防止対策用ウイルス除去膜とその新展開  [in Japanese] Novel Application of Virus Removal Membrane Developed in Order to Minimize Virus Infection from Bio-drugs  [in Japanese]

Access this Article

Search this Article

Author(s)

Abstract

The high level of removability of virus in the purification process of bio-drugs such as 5 logs removal draws the new concept of membrane structure. The novel structure is represented by the multi-layers, each of which shows the characteristics of a screen filter, resulting in the multi-steps filtration. In this review the preparation method of the membrane with multi-layers and its performance of virus removal and protein permeability are dealed with. In order to apply the me-mbrane in the actual purification process, the membrane should be validatable, that is, reproducible and predictable in virus removal. The combination of two type tests of a breakage and a non-breakage tests is employed in the manufacturing process of the membrane. The test for the confirmation of mean characteristic values such as mean pore size is an example of breakage tests and the pressure hold test is one of non-breakage tests. This combination makes the membrane validatable. The users of this membrane should carry out the integrity test developed for the membrane manufacturer. The target particle to be removed spread widely such as prion proteins and DNA. The mechanism of separation of fine particles has been clarified and then, the new separation method of diffusion using the membrane may be succesful in future.

Journal

  • MEMBRANE

    MEMBRANE 27(1), 2-8, 2002-01-01

    THE MEMBRANE SOCIETY OF JAPAN

References:  37

  • <no title>

    STARKS P. T.

    Nature 389(6650), 448, 1997

    Cited by (1)

  • <no title>

    Commision of the European Community

    Validation of virus removal and inactivation, 1991

    Cited by (1)

  • <no title>

    ELFORD W. J.

    Proc. Roy. Soc., Lond., B 112, 384, 1933

    Cited by (1)

  • <no title>

    HE Li. F.

    J. Infect. Dis. (United States) 156(4), 636, 1987

    Cited by (1)

  • <no title>

    YUASA T.

    J. Gen. Viral. 72, 2021, 1991

    Cited by (2)

  • <no title>

    MUCHMORE E.

    Int. Symp. Viral Hepatitis Liver Dis. 8196, 1993

    Cited by (1)

  • <no title>

    MARIKO M.

    Arch. Virol. 130, 139, 1994

    Cited by (1)

  • <no title>

    真鍋征一

    精密濾過-膜分離プロセスの理論と設計 135, 1993

    Cited by (1)

  • <no title>

    真鍋征一

    精密濾過-膜分離プロセスの理論と設計 184, 1993

    Cited by (1)

  • <no title>

    KAMIDE K.

    Polymer J. 21(3), 241, 1989

    Cited by (1)

  • <no title>

    真鍋征一

    ウイルス分離(高分子の物性(3) 493, 1995

    Cited by (1)

  • <no title>

    真鍋征一

    特公昭48-25055, 1973

    Cited by (2)

  • <no title>

    真鍋征一

    特公平03-068058, 1991

    Cited by (2)

  • <no title>

    KAMIDE K.

    Materials Science of Synthetic Membranes 197, 1985

    Cited by (1)

  • <no title>

    真鍋征一

    特開昭61-274707

    Cited by (1)

  • <no title>

    MANABE S.

    usp 4808315, 1989

    Cited by (2)

  • <no title>

    TSURUMI T.

    Polymer J. 22(2), 1085, 1990

    Cited by (1)

  • <no title>

    MANABE S.

    Biomedical Review 6, 95, 1996

    Cited by (1)

  • <no title>

    ISHIKAWA G.

    Membrane 16, 101, 1991

    Cited by (2)

  • <no title>

    NAKANO H.

    Animal Cell TechnologyBasic and Applied Aspects 4, 87, 1992

    Cited by (1)

  • <no title>

    NODA T.

    Animal Cell Technology, Basic and Applied Aspects 6, 523, 1994

    Cited by (1)

  • Viral Safety and Evaluation of Viral Clearance from Phamaceutical Products

    MANABE S.

    Dev. Biol. Stand. 88, 81, 1996

    Cited by (1)

  • <no title>

    HIRASAKI T.

    Membrane 19, 135, 1995

    Cited by (1)

  • <no title>

    林田康宏

    医学のあゆみ 152, 183, 1990

    Cited by (1)

  • <no title>

    立石潤

    膜 18, 357, 1993

    Cited by (1)

  • <no title>

    BURNOUF T.

    Preprint in PLANOVA^<TM> Workshop 69, 1998

    Cited by (1)

  • <no title>

    TATEISHI J.

    Biologicals 29, 17, 2001

    Cited by (2)

  • <no title>

    CENTER FOR BIOLOGICS Evaluation and Research Food and Drug Administration (FDA USA)

    Points to consider in the characterization of cell lines used to produce biologicals, 1-40, 1993

    Cited by (2)

  • <no title>

    HIRASAKI T.

    J. Membrane Sci. 106, 123, 1995

    Cited by (2)

  • <no title>

    HIGUCHI A.

    J. Membrane, Sci. 186, 9, 2001

    Cited by (2)

  • <no title>

    MIZUSAWA S.

    Animal Cell Technology, Basic and Applied Aspects 6, 537, 1994

    Cited by (1)

  • <no title>

    MANABE S.

    Bull. Fac. Human Environmental Sci., Fukuoka Women's Univ. 32, 71, 2001

    Cited by (2)

  • <no title>

    藤岡留美子

    福岡女子大学人間環境学部紀要 29, 29, 1998

    Cited by (1)

  • <no title>

    LOSIKOFF A.

    Genetic Engineering News 19(8), 1999

    Cited by (1)

  • Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent

    BRUCE M. E.

    Nature 389, 498-501, 1997

    DOI  Cited by (30)

  • <no title>

    STARKS P. T.

    Nature 389(6650), 423, 1997

    DOI  Cited by (1)

  • <no title>

    中川由紀

    繊維学会予稿集2001 56(1), 205, 2001

    Cited by (1)

Codes

  • NII Article ID (NAID)
    10008010917
  • NII NACSIS-CAT ID (NCID)
    AN0023215X
  • Text Lang
    JPN
  • Article Type
    REV
  • ISSN
    03851036
  • NDL Article ID
    6058582
  • NDL Source Classification
    ZR2(科学技術--生物学--生化学)
  • NDL Call No.
    Z18-1127
  • Data Source
    CJP  NDL  J-STAGE 
Page Top